ABION Inc. (KOSDAQ:203400)
South Korea · Delayed Price · Currency is KRW 3,380.00
-70.00 (-2.03%)
At close: Aug 14, 2026
ABION Revenue
ABION had revenue of 136.98M KRW in the quarter ending June 30, 2026, a decrease of -35.47%. This brings the company's revenue in the last twelve months to 939.70M, down -7.98% year-over-year. In the year 2025, ABION had annual revenue of 880.14M with 15.86% growth. That makes ABION the 44,086th largest company in the world by revenue and 2,589th in South Korea.
Revenue (ttm)
939.70M
Revenue Growth
-7.98%
P/S Ratio
64.82
Revenue / Employee
27.64M
Employees
34
Market Cap
60.91B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 880.14M | 120.45M | 15.86% |
| Dec 31, 2024 | 759.68M | -514.62M | -40.38% |
| Dec 31, 2023 | 1.27B | -1.23B | -49.16% |
| Dec 31, 2022 | 2.51B | 868.02M | 52.98% |
| Dec 31, 2021 | 1.64B | -355.32M | -17.82% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CTCBIO | 131.54B |
| KoBioLabs | 75.41B |
| Psomagen | 60.70B |
| Naturalendo Tech | 22.79B |
| PanGen Biotech | 14.18B |
| ADBiotech | 12.57B |
| QuadMedicine | 7.14B |
| TegoScience | 6.18B |